NNI-351 explained

NNI-351 is an orally active inhibitor of and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD).^{[1] [2]} As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials. In July 2022, NNI-351 was granted orphan drug status by the FDA for the treatment of Fragile X syndrome.^[3]

See also

• List of investigational antidepressants

External links

• NNI-351 - NeuroNascent, Inc
• NNI-351 - AdisInsight
• Methods and pharmaceutical compositions for treating down syndrome (patent)

Notes and References

1. Web site: Research programme: Psychiatric and neurological disorders therapeutics - Neuronascent - AdisInsight.
2. Froestl W, Muhs A, Pfeifer A . Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes . J. Alzheimer's Dis. . 33 . 3 . 547–658 . 2013 . 23042218 . 10.3233/JAD-2012-121537 . 34896894 .
3. Web site: Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome . GlobeNewswire News Room . GlobalNewsWire . 15 January 2023 . en . 1 June 2022.